Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
View Patent ↗Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
1. A solid pharmaceutical composition comprising rifaximin in polymorphic Form α and a pharmaceutically acceptable excipient or carrier, wherein the rifaximin Form α has x-ray powder diffraction pattern peaks at about 7.4°; 19.7°; 21.0° and 22.1° 2-θ, wherein the rifaximin Form α has a water content of between 3.0-4.5%.
2. The pharmaceutical composition of claim 1 , wherein the rifaximin Form α has a water content of 3.0%.
3. The pharmaceutical composition of claim 1 , wherein the rifaximin Form α has a water content of 4.5%.
4. The pharmaceutical composition of claim 1 , wherein the excipient is selected from the group consisting of a diluting agent, a binding agent, a lubricating agent, a disintegrating agent, a coloring agent, a flavoring agent, and a sweetening agent.
5. The pharmaceutical composition of claim 1 , wherein the composition is for oral use and is in a form selected from the group consisting of coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets, and powders in sealed packet.
6. The pharmaceutical composition of claim 1 , wherein the composition further comprises an ingredient selected from the group consisting of colloidal silicon dioxide, hydroxypropyl methylcellulose, cellulose, microcrystalline cellulose, propylene glycol, sodium starch glycolate, talc, and a combination thereof.
7. The pharmaceutical composition of claim 1 , further comprising rifaximin in polymorphic Form β having x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9° 2-θ.
8. The pharmaceutical composition of claim 1 , further comprising rifaximin in polymorphic Form γ having x-ray powder diffraction pattern peaks at about 5.0°, 7.1°, and 8.4° 2-θ.
9. A solid pharmaceutical composition comprising rifaximin in polymorphic Form β and a pharmaceutically acceptable excipient or carrier, wherein the rifaximin Form β has x-ray powder diffraction pattern peaks at about 5.4°; 9.0°; and 20.9° 2-θ and wherein the rifaximin Form β has a water content of between 4.5%-5.0%.
10. The pharmaceutical composition of claim 9 , wherein the rifaximin Form β has a water content of 5.0%.
11. The pharmaceutical composition of claim 9 , wherein the excipient is selected from the group consisting of a diluting agent, a binding agent, a lubricating agent, a disintegrating agent, a coloring agent, a flavoring agent, and a sweetening agent.
12. The pharmaceutical composition of claim 9 , wherein the composition is for oral use and is in a form selected from the group consisting of coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets, and powders in sealed packet.
13. The pharmaceutical composition of claim 9 , wherein the composition further comprises an ingredient selected from the group consisting of colloidal silicon dioxide, hydroxypropyl methylcellulose, cellulose, microcrystalline cellulose, propylene glycol, sodium starch glycolate, talc, and a combination thereof.
14. The pharmaceutical composition of claim 9 , further comprising rifaximin in polymorphic Form γ having x-ray powder diffraction pattern peaks at about 5.0°, 7.1°, and 8.4° 2-θ.
15. A solid pharmaceutical composition comprising rifaximin in polymorphic Form γ and a pharmaceutically acceptable excipient or carrier, wherein the rifaximin Form γ has x-ray powder diffraction pattern peaks at about 5.0°, 7.1°, and 8.4° 2-θ and wherein the rifaximin Form γ has a water content of from between 0% to 1%.
16. The pharmaceutical composition of claim 15 , wherein the rifaximin Form γ has a water content of 0%.
17. The pharmaceutical composition of claim 15 , wherein the rifaximin Form γ has a water content of 1%.
18. The pharmaceutical composition of claim 15 , wherein the excipient is selected from the group consisting of a diluting agent, a binding agent, a lubricating agent, a disintegrating agent, a coloring agent, a flavoring agent, and a sweetening agent.
19. The pharmaceutical composition of claim 15 , wherein the composition is for oral use and is in a form selected from the group consisting of coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets, and powders in sealed packet.
20. The pharmaceutical composition of claim 15 , wherein the composition further comprises an ingredient selected from the group consisting of colloidal silicon dioxide, hydroxypropyl methylcellulose, cellulose, microcrystalline cellulose, propylene glycol, sodium starch glycolate, talc, and a combination thereof.